Ryan White Clinics Call on Congress, HHS, & HRSA to Stop Drug Manufacturers from Undermining Our Use of the 340B Program to Care for People with HIV
ACTIONS, MOTIONS & COMPLAINTS
- CHART: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary (Updated 7/7/2023)
- Amicus Brief by RWC-340B and Others: Novo Nordisk v. Becerra (7/2/2021)
- Amicus Brief by RWC-340B and Others: Novartis v. Becerra (7/2/2021)
- Amicus Brief by RWC-340B and Others: Eli Lilly v. Becerra (6/21/2021)
- Amicus Brief by RWC-340B and Others: AstraZeneca v. Becerra (5/4/2021)
- Motion for Immediate Temporary Relief in RWC-340B v Azar (11/23/20)
- Amended Complaint: RWC-340B v Azar (11/23/20)
- Complaint Filed: RWC-340B v Azar (Oct. 9, 2020)
LETTERS OF ACTION
- Spanberger to HHS Secretary Xavier Becerra: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes (January 25, 2022)
- Bipartisan Congressional Sign on Letter: Regarding Recent Manufacturer Actions in the 340B Program (September 14, 2020)
- Letter to HHS Secretary Alex Azar: Manufacturer Actions Violating 340B Statute Requirements (September 14, 2020)
- Direct Patient Benefits: Why Making 340B a Direct Patient Benefit Would Harm Ryan White HIV Patients
PRESS RELEASES & STATEMENTS
- Press Release: RWC-340B and 340B Grantee Plaintiffs File Lawsuit to Protect 340B Contract Pharmacy Program from Manufacturer Attacks That Are Undermining Patient Care and Public Health
- Press Statement: “Ryan White Clinics Call on Congress, HHS, & HRSA to Stop Drug Manufacturers from Undermining Our Use of the 340B Program to Care for People with HIV (August 27, 2020)
- Press Release: Dozens of Attorneys General and Hundreds of Members of Congress Agree with RWC-340b: Manufacturers’ Actions Against 340B Undermine the Safety Net (December 15, 2020)